Browse by author
Lookup NU author(s): Dr Ismael Atchia, Dr Richard Holleyman, Ajay MalviyaORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2025 Lippincott Williams and Wilkins. All rights reserved.Background: Greater trochanteric pain syndrome (GTPS) is a painful condition that can impair a patient’s quality of life. If nonoperative measures fail, progressively more invasive treatment options may be required. This clinical trial aimed to evaluate the effectiveness of ultrasound-guided leukocyte-rich platelet-rich plasma (LR-PRP) injections in the treatment of refractory GTPS caused by bursitis and/or gluteal tendinopathy. Methods: An ethically approved, adequately powered, double-blinded randomized controlled trial (RCT) was conducted to evaluate the clinical outcomes in randomized LR-PRP and placebo groups using the International Hip Outcome Tool-12 (iHOT-12), a visual analogue scale (VAS) for pain, the modified Harris hip score (mHHS), the EuroQol 5-Dimensions (EQ-5D) questionnaire, and the presence or absence of complications. All injections were performed under ultrasound guidance into the trochanteric bursa and gluteus medius tendon. Results: The final analysis included 79 patients (39 in the LR-PRP and 40 in the placebo group; 73 female and 6 male; all Caucasian). Both the LR-PRP and the placebo group generally had improvement from baseline that was maintained to 12 months. The only deterioration in scores compared to baseline was seen in the LR-PRP group for the iHOT-12 at 12 months, the EQ-5D index at 3 and 6 months, and the EQ-5D VAS at all follow-up time points. However, there was no significant difference between the 2 groups at any follow-up point (p > 0.05). A multivariable linear regression model, with adjustment for age, sex, body mass index, and preoperative baseline score, did not reveal any significant associations between iHOT-12 and EQ-5D score gains at 12 months and treatment. Conclusions: This randomized trial found no significant difference in outcomes between LR-PRP and placebo for the treatment of greater trochanteric pain up to 6 months following the intervention. As a result, we do not support the routine use of PRP for the treatment of this condition.
Author(s): Atchia I, Ali M, Oderuth E, Holleyman R, Malviya A
Publication type: Article
Publication status: Published
Journal: Journal of Bone and Joint Surgery
Year: 2025
Pages: epub ahead of print
Online publication date: 13/01/2025
Acceptance date: 02/04/2018
ISSN (print): 0021-9355
ISSN (electronic): 1535-1386
Publisher: Lippincott Williams and Wilkins
URL: https://doi.org/10.2106/JBJS.24.00763
DOI: 10.2106/JBJS.24.00763
Altmetrics provided by Altmetric
